Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab Soravtansine in TNBC with Residual Disease
NCT03045393Phase 1Withdrawn
- Sponsor
- Duke University
- Start
- Apr 2017
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mirvetuximab soravtansine in triple-negative breast cancer (TNBC), sponsored by Duke University. Primary endpoint: Change in breast tumor FRα expression before and after treatment with mirvetuximab soravtansine at 9 weeks. Planned start Apr 2017; status: withdrawn.
02
Drugs
mirvetuximab soravtansine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03045393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03045393.